Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Somnigroup International Inc. Common Stock (SGI) vs Zoetis Inc (ZTS) Price & Performance

Somnigroup International Inc. Common StockTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Somnigroup International Inc. Common Stock vs Zoetis Inc — how do they compare? Somnigroup International Inc. Common Stock trades at $62.83 (market cap $14.48B), while Zoetis Inc trades at $75.78 (market cap $30.70B). The key difference: Zoetis Inc is far larger — about 2.1× Somnigroup International Inc. Common Stock's market cap, and Zoetis Inc pays the higher dividend (2.85%). Which is the better fit depends on your goals — on Pluang, investors hold Somnigroup International Inc. Common Stock for 0 Days and Zoetis Inc for 71 Days on average.

SGIZTS
Market Cap
$14.48B$30.70B
Volume
1,734,3993,299,421
Sector
Consumer CyclicalHealth
52-Week High
$97.99$147.53
52-Week Low
$61.49$69.09
Typical Hold Time
0 Days71 Days
Enterprise Value
$20.78B$38.27B
Dividend Yield
1.08%2.85%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Somnigroup International Inc. Common Stock

Somnigroup International (SGI) trades at $62.87, up 0.75% with neutral technical signals. The company shows strong profitability with 44.24% gross margins and has beaten earnings estimates for three consecutive quarters. Recent acquisition of Leggett & Platt enhances vertical integration with $75M synergy target. Analyst consensus is strongly bullish with 91% buy ratings and $94.50 price target, representing 50% upside potential from current levels.

SGI presents compelling growth prospects through strategic acquisitions and operational efficiencies, though faces margin pressures in weak bedding markets. The stock trades at reasonable valuations (P/E 24.85) with improving cash flow trends expected in 2026. Key risks include integration execution and market competition, but strong institutional interest and insider buying support the bullish case.

Zoetis Inc

Zoetis (ZTS) trades at $74.30, down 1.78% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 27.69% net income margin and 64.91% ROE, though recent Q1 2026 earnings missed expectations. Revenue growth has been steady, reaching $9.47B in 2025, while analyst consensus price target sits at $87.33 with 46.88% buy ratings. Recent news highlights competitive pressures in the U.S. companion animal market but acknowledges the company's industry-leading margins.

ZTS presents a compelling value opportunity with a P/E of 12.12 below sector averages, supported by robust cash flow generation and dividend payments. Near-term risks include U.S. market weakness and competitive pressures, but long-term growth drivers in international and livestock segments provide upside potential. The stock's current valuation reflects these headwinds, creating potential for appreciation as business conditions stabilize.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SGI
100% Buy0% Sell
Avg holding period · 0 Days
ZTS
0% Buy100% Sell
Avg holding period · 71 Days

About Somnigroup International Inc. Common Stock

Somnigroup International Inc. (formerly Tempur Sealy International) is a bedding and sleep-products company that designs, manufactures, distributes, and retails mattresses and related products. It operates through Tempur Sealy North America, Tempur Sealy International, and Mattress Firm, with brands including Tempur-Pedic, Sealy, Stearns & Foster, and Mattress Firm.

Read more on SGI →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →